2022年美国心脏协会科学年会（AHA 2022）将于当地时间11月5日~7日以线上+线下相结合的方式在美国芝加哥盛大召开。作为国际心血管盛会，今年AHA 将揭晓哪些重磅研究结果？目前官网日程已上线，小编整理了9个最新科学研究（Late Breaking Science）专场即将发布的研究，您期待哪一个呢？
2022年美国心脏协会科学年会（AHA 2022）将于当地时间11月5日~7日以线上+线下相结合的方式在美国芝加哥盛大召开。作为国际心血管盛会，今年AHA 将揭晓哪些重磅研究结果？目前官网日程已上线，小编整理了9个最新科学研究（Late Breaking Science）专场即将发布的研究，您期待哪一个呢？
LBS.01 改变临床实践的重大事件
时间：11月5日（星期六），9:30 AM – 10:30 AM
Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
TRANSFORM-HF试验主要结果：托拉塞米和呋塞米治疗心力衰竭的疗效比较
Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension
DCP研究：比较氯噻酮和氢氯噻嗪预防高血压患者心血管事件的效果
A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
PROMINENT试验：Pemafibrate降低甘油三酯对心血管疾病预防作用的随机试验
LBS.02 心力衰竭突破性治疗策略
时间：11月5日（星期六），3:00 PM – 4:00 PM
First-in-Human in vivo Crispr/Cas9 Editing of the Ttr Gene by Ntla-2001 in Patients with Transthyretin Amyloidosis With Cardiomyopathy
体内CRISPR/Cas9基因编辑疗法Ntla-2001用于甲状腺素蛋白淀粉样变心肌病的首个人体试验结果
A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial
COACH试验：在急性心力衰竭护理中，基于患者风险的健康系统干预作用
Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial
PRO-HF试验：患者报告的心力衰竭临床结局测量试验的初步结果
Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure with Reduced Ejection Fraction
IRONMAN试验：静脉注射Ferric Derisomaltose治疗射血分数降低的心力衰竭患者的随机试验
LBS.03 介入和手术的高影响力试验
时间：11月6日（星期日），8:00 AM – 9:00 AM
Radial Artery Patency and Clinical Outcomes (RAPCO) Randomized Trials – The 15-Year Clinical Outcomes Comparing Radial Artery with Right Internal Thoracic Artery or With Saphenous Vein Grafting
桡动脉通畅性和临床结局（RAPCO）试验：桡动脉与右胸内动脉/隐静脉移植的15年预后比较
Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The Stress Trial
STRESS试验：类固醇可减少婴儿心脏手术后的全身炎症
The Impact of Chinese Herbal Medicine， Tongxinluo in Patients with Acute Myocardial Infarction – Results From the CTS-AMI Trial
CTS-AMI试验结果：中药通心络对急性心肌梗死患者的影响
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results from the Multicenter， Randomized ECMO-CS Trial
ECMO-CS试验的主要结果：体外膜肺氧合治疗心源性休克的多中心随机试验
LBS.04 慢性高血压管理的正念干预
时间：11月6日（星期日），3:30 PM – 4:30 PM
Effectiveness of a Village Doctor-Led Multifaceted Implementation Strategy on Cardiovascular Disease Among Patients with Hypertension: A Cluster Randomized Trial
CRHCP集群随机试验：乡村医生主导的心血管疾病防治多方位实施策略对高血压患者心血管疾病防治的有效性
Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone: Blood Pressure and Patient-Reported Outcomes
Rich Life Project研究：减少高血压护理中的不平等，改善每个人的生活方式：血压和患者报告的结果
The Effect of Adapted Mindfulness Training in Participants with Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial
MB-BP随机临床试验：正念训练对诊室血压升高患者的影响
Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension (QUARTET USA): A Randomized Controlled Trial
QUARTET USA随机对照试验：四联超低剂量治疗高血压的疗效和安全性
LBS.05 改变心血管和肾脏疾病的预防方式
时间：11月6日（星期日），5:00 PM – 6:00 PM
Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid
RESPECT-EPA试验：评价他汀类药物和二十碳五烯酸联合治疗用于心血管疾病二级预防效果的随机试验
Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial
Ocean(a)-DOSE试验：小干扰RNA降低脂蛋白(a)水平
Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial
EMPA-KIDNEY试验：恩格列净对慢性肾脏疾病患者心血管结局的影响
Effect of Low-Dose Statin Compared with Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial
SPORT随机临床试验：与安慰剂和6种膳食补充剂相比，低剂量他汀对血脂和炎症生物标志物的影响
LBS.06 ACS和血运重建患者的治疗策略
时间：11月6日（星期日），5:00 PM – 6:00 PM
Bivalirudin With a Post-PCI High-Dose Infusion versus Heparin Monotherapy During Primary PCI in STEMI: The Randomized Bright-4 Trial
BRIGHT-4随机试验：STEMI患者直接PCI术后大剂量输注比伐卢定与肝素单药治疗的比较
Efficacy and Safety of Indobufen versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized， Open-Label， Non-Inferiority Trial
OPTION试验：一项随机、开放标签、非劣效性试验，评估冠状动脉药物洗脱支架置入后吲哚布芬 vs. 阿司匹林的疗效和安全性
Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial
PRECISE随机试验：在病情稳定的疑似冠状动脉疾病患者中，精准管理策略和常规管理策略的比较
ISCHEMIA-EXTENDed Follow-Up Interim Report
ISCHEMIA-EXTENDed：ISCHEMIA试验后续中期报告
LBS.07 外周血管疾病的血管介入和药物治疗
时间：11月7日（星期一），8:00 AM – 9:00 AM
Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia - Clinical Results
BEST-CLI临床结果：慢性肢体威胁性缺血患者的最佳血管内治疗与最佳手术治疗
Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia - Quality of Life Analyses
BEST-CLI生活质量分析 (QOL) ：慢性肢体威胁性缺血患者的最佳血管内治疗与最佳手术治疗
Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events， Hospitalization and Death in Medically Ill Outpatients with Covid-19: Primary Results of the PREVENT-HD Randomized Clinical Trial
PREVENT-HD随机临床试验的主要结果：在COVID-19门诊患者中，利伐沙班可降低主要静脉和动脉血栓事件、住院和死亡风险
A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically-Ill Patients
IMPROVE：一项多中心集群随机试验，基于通用电子健康记录的静脉血栓栓塞风险评估模型用于住院内科患者血栓栓塞预防的综合临床决策支持
LBS.08 房性和室上性心律失常的治疗
时间：11月7日（星期一），11:00 AM – 12:00 PM
The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The Progressive-AF Trial
PROGRESSIVE-AF试验：“一线”节律治疗对房颤进展的影响
Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the Rapid Study
RAPID研究初步分析结果：Etripamil自行给药终止自发性阵发性室上性心动过速
Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results from the Phase 2 Nova Study
NOVA 2期研究结果：A型肉毒毒素预防心脏手术患者术后房颤的疗效和安全性
Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway
ENHANCE-AF试验：评估房颤卒中预防共享决策路径
LBS.09 难治性高血压的管理
时间：11月7日（星期一），3:00 PM – 4:00 PM
Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (FRESH) Study
FRESH研究Top-Line结果：First-in-Class药物氨基肽-A抑制剂Firibastat治疗难治性高血压
Sustained Blood Pressure Lowering Effect with the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results from a Randomized， Controlled Study Including a Withdrawal Phase
PRECISION随机对照研究（包括退出期）：双内皮素受体拮抗剂Aprocitentan对难治性高血压的持续降压作用
Results from a Phase 2， Randomized， Double-Blind， Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
BrigHTN试验：一项2期、随机、双盲、安慰剂对照试验，评估Baxdrostat在难治性高血压患者中疗效和安全性
Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results from the SPYRAL HTN-ON Med Expansion Randomized Trial
SPYRAL HTN-ON扩展随机试验的6个月主要结果：在接受降压药物治疗的患者中，射频消融去肾交感神经术对血压的影响
声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
京公网安备 11010502033353号